Este protocolo aplica-se a pacientes com taquicardia ventricular polimórfica catecolaminérgica (CPVT) que apresentaram síncope arrítmica ou possuem taquicardia ventricular bidirecional ou polimórfica documentada, e que não sofreram parada cardíaca abortada.
DOI: 10.1093/eurheartj/ehac262
Flecainide should be considered in patients with CPVT who experience recurrent syncope, polymorphic/bidirectional VT, or persistent exertional PVCs, while on beta-blockers at the highest tolerated dose.
ICD implantation should be considered in patients with CPVT who experience arrhythmogenic syncope and/or documented bidirectional/PVT while on highest tolerated beta-blocker dose and on flecainide.
LCSD should be considered in patients with diagnosis of CPVT when the combination of beta-blockers and flecainide at therapeutic dosage are either not effective, not tolerated, or contraindicated.
View source ↗